TERT and non-small cell lung carcinoma: Regardless the immune parameters, the median OS was 13 months in the metastatic population and not reached in localised patients, which is in line with the literature (data not shown).31,32 We found that NSCLC patients who exhibited high rates of anti-TERT Th1 cells (anti-TERT Th1high) had better median OS compared with patients with anti-TERT Th1low (not reached versus 12 months, P = 0.009).